IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Roswell Park Comprehensive Cancer Center · University of Iowa · +10 more institutions
Abstract
PURPOSE To analyze the frequency and associations with prognostic markers and outcome of mutations in IDH genes encoding isocitrate dehydrogenases in adult de novo cytogenetically normal acute myeloid leukemia (CN-AML). PATIENTS AND METHODS Diagnostic bone marrow or blood samples from 358 patients were analyzed for IDH1 and IDH2 mutations by DNA polymerase chain reaction amplification/sequencing. FLT3, NPM1, CEBPA, WT1, and MLL mutational analyses and gene- and microRNA-expression profiling were performed centrally. Results IDH mutations were found in 33% of the patients. IDH1 mutations were detected in 49 patients (14%; 47 with R132). IDH2 mutations, previously unreported in AML, were detected in 69 patients…
Citation impact
- FWCI
- 40.75
- Percentile
- 100%
- References
- 66
Authors
20- GMGuido MarcucciCorresponding
Roswell Park Comprehensive Cancer Center
- KMKati Maharry
University of Iowa, University of Maryland, Baltimore, Roswell Park Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, North Shore University Hospital, University of Alabama at Birmingham, University of Illinois Chicago, University of Chicago, Duke Medical Center, Duke University Hospital, Wake Forest University, The Ohio State University
- YWYue-Zhong Wu
University of Iowa, University of Maryland, Baltimore, Roswell Park Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, North Shore University Hospital, University of Alabama at Birmingham, University of Illinois Chicago, University of Chicago, Duke Medical Center, Duke University Hospital, Wake Forest University, The Ohio State University
- MDMichael D. Radmacher
University of Iowa, University of Maryland, Baltimore, Roswell Park Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, North Shore University Hospital, University of Alabama at Birmingham, University of Illinois Chicago, University of Chicago, Duke Medical Center, Duke University Hospital, Wake Forest University, The Ohio State University
- KMKrzysztof Mrózek
University of Iowa, University of Maryland, Baltimore, Roswell Park Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, North Shore University Hospital, University of Alabama at Birmingham, University of Illinois Chicago, University of Chicago, Duke Medical Center, Duke University Hospital, Wake Forest University, The Ohio State University
Topics & keywords
- IDH2
- NPM1
- CEBPA
- Myeloid leukemia
- IDH1
- Cancer research
- Leukemia
- Biology
- Good health and well-being